08/29/2026
"Inherited retinal diseases (IRDs) are a genetically and clinically heterogeneous group of disorders caused by pathogenic variants in more than 250 genes.1,2 Mutation-specific gene augmentation and gene editing have transformed care for a small subset of patients, yet the sheer genetic diversity and cost of developing “one therapy per gene” mean that most individuals with an IRD still lack an approved treatment.1,2 As a result, gene-agnostic strategies may broaden treatment options by targeting shared downstream pathways rather than individual mutations.3-5 These broader therapeutic approaches aimed at preserving or restoring vision are gaining increasing attention.1"
Emerging gene-agnostic strategies target shared pathways and offer options for IRD patients without mutation-specific therapies.